Clinical Trial Update: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Dose Adjusted EPOCH combined with either ofatumumab or rituximab in newly diagnosed or relapsed/refractory Burkitt lymphoma and relapse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Aids-related Burkitt Lymphoma
• Atypical Burkitt Burkitt-like Lymphoma
• Burkitt Lymphoma
• High-grade B-cell Lymphoma with Myc Bcl2 and Bcl6 Rearrangements
• High-grade B-cell Lymphoma with Myc and Bcl2 or Bcl6 Rearrangements

Drugs mentioned

• Dose Adjusted EPOCH
• Ofatumumab (ofatumumab)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-11